national stem-cell therapy logo

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

biorestorative therapies logo

MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting in Uniondale, NY on April 29th – 30th, 2022 for the Company’s lead clinical candidate BRTX-100®, an autologous bone […]